Openbookopenbook
Equity
Elekta AB ser. B(0O5H)
SEK --+0.00%
Reward50Moderate
Risk25Low
📊50%Data
Thin -0% profit margin · 3.2% dividend yield · Revenue down 10% YoY
0O5H
+0.0 · +0.00%
SEK · LSE
Elekta AB ser. B |
Earnings Deterioration
Market Cap:35.60Bn
ℹ️
Reward Rating
50
Moderate
Bottom 50% (model universe)
50% data coverage
ℹ️
Risk Rating
25
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on 0O5H to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: kr75.20.

What is Elekta AB ser. B?

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

0O5H · Verdict

Moderate reward · low risk

0O5H stands out on cash flow and balance sheet, but watch the profitability signal.

Based on 75% data coverage

0O5H · Verdict

What’s working & what to watch

Strengths 2

  • Cash flow95/100

    Top decile vs peers

  • Balance sheet75/100

    Current ratio 1.11

Watchouts 1

  • Profitability24/100

    -0% return on equity

Model-based scoring. For information only — not financial advice.

What is Elekta AB ser. B?

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers linear accelerator and radiation therapy products comprising Elekta Unity for anatomy-specific MR imaging; Elekta Evo that delivers offline and online adaptive radiation therapy; Elekta Versa HD, a brain metastases solution; Elekta Harmony; and Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs, as well as quality assurance, and treatment and motion management solutions. The company is listed on the LSE in UK, with a market capitalisation of 35.60B.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (50)

The scoring profile indicates limited reward potential at this time, with valuation and growth offering the most support. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorN/A
Market Cap35.60B
P/E RatioN/A
Dividend Yield3.23%
52 Week High65.2123
52 Week Low41.3206
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares OutstandingN/A
No. of Employees4,438
IndustryN/A
ExchangeLSE
Beta1.011
CurrencySEK
Websitewww.elekta.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.